Major changes are on the horizon for millions of Americans who rely on high-cost prescription medications. In a landmark move, the federal government has announced exact price cuts for several blockbuster drugs, including Eliquis and Jardiance, set to take effect in 2026.
This article breaks down the details of these price reductions, what they mean for patients, and the broader impact on the healthcare system.
Background: The Push for Lower Drug Prices
For years, the high cost of prescription drugs in the United States has been a major concern for patients, healthcare providers, and policymakers alike. In response, the Inflation Reduction Act of 2022 granted Medicare the authority to negotiate prices for certain high-spending drugs. After months of negotiation and analysis, the Centers for Medicare & Medicaid Services (CMS) has revealed the exact price cuts for the first wave of drugs, with changes set to begin in 2026.
The 2026 Price Cuts: Which Drugs Are Affected?
The initial list of drugs subject to Medicare price negotiations includes some of the most widely prescribed and expensive medications for chronic conditions. Among the most notable are Eliquis (apixaban), a blood thinner used to prevent strokes and blood clots, and Jardiance (empagliflozin), a popular treatment for type 2 diabetes and heart failure. Other drugs on the list include Xarelto, Januvia, Farxiga, and Enbrel, among others.
Exact Price Reductions Revealed
According to the finalized agreements, the following are the projected price cuts for 2026:
Eliquis: Price reduced by approximately 50%, lowering the annual cost from around $6,700 to $3,350 for Medicare beneficiaries.
Jardiance: Price cut by about 45%, reducing the yearly expense from $6,600 to $3,630.
Xarelto: Price slashed by 44%, from $6,200 to $3,472 per year.
Januvia: Price reduced by 40%, from $6,200 to $3,720 annually.
Farxiga: Price cut by 38%, from $6,500 to $4,030 per year.
Enbrel: Price reduced by 35%, from $12,000 to $7,800 annually.
These reductions are based on CMS-negotiated prices and are expected to be reflected in Medicare Part D plans starting in 2026.
What This Means for Patients
The price cuts are poised to deliver significant savings for millions of Medicare beneficiaries who depend on these medications. Out-of-pocket costs for patients are expected to drop substantially, making life-saving treatments more accessible and reducing the financial burden on seniors and those with chronic illnesses. Additionally, the new pricing structure may influence private insurers to negotiate lower prices, potentially benefiting a broader population.
Broader Implications for the Healthcare System
The 2026 drug price cuts mark a historic shift in how prescription drug prices are determined in the U.S. healthcare system. Pharmaceutical companies may face pressure to adjust their pricing strategies, and the move could set a precedent for future negotiations. While some industry groups have raised concerns about potential impacts on innovation, advocates argue that the changes will foster greater affordability and access to essential medications.
Looking Ahead
As the countdown to 2026 continues, patients, providers, and policymakers will be watching closely to see how these price cuts are implemented and whether they deliver the promised savings. The success of this initiative could pave the way for further reforms aimed at making prescription drugs more affordable for all Americans.